SOUTH EASTON, Mass., Oct. 8 /PRNewswire-FirstCall/ -- Pressure BioSciences, Inc. (Nasdaq: PBIO) ("PBI") today provided an update on various corporate activities, including the presentation of favorable data generated by scientists at Amgen, Inc. on the Company's pressure cycling technology ("PCT"), the scheduled presentation by Dr. Paul Pevsner of the NYU School of Medicine on the use of PCT in identifying potential protein biomarkers in colon cancer samples, and guidance relative to forecasted Q32008 and FY2008 sales of the Company's Barocycler instruments.
1) Amgen Presentation: data were presented by scientists from Amgen at the 35th meeting of the Federation of Analytical Chemistry and Spectroscopy Societies (FACSS) comparing PCT to their standard overnight procedure and the popular CEM, Inc. microwave-assisted technique for the digestion of a therapeutic monoclonal antibody. Amgen scientists reported that, "Pressure cycling was shown to be most effective at achieving complete digestion in a short time, without unintended perturbation of the molecule. Microwave digestion did not achieve complete digestion and induced oxidation of methionine residues." The authors concluded that, "PCT represents an increase in throughput and efficiency of at least 20-fold over the current conditions ... pressure cycling provided the most effective method for digesting monoclonal antibodies."
2) Dr. Paul Pevsner Presentation: Dr. Pevsner, Associate Professor of Pharmacology at the NYU School of Medicine, is scheduled to speak at the "Discovery2Diagnostics" Conference (San Diego, CA) on Monday, October 20th. Dr. Pevsner's talk, entitled "MALDI Imaging and Mass Spectrometry Identification of Colorectal Cancer Biomarkers", will include a discussion on the advantages of PCT versus other sample preparation methods available today. Dr. Pevsner is also expected to present data on the discovery of several proteins that he and his colleagues have found in colon cancer samples using PCT that have not been previously found in similar samples using other sample preparation techniques.
3) Guidance on Barocycler Sales: on August 14th, the Company announced that it expected to install at least fourteen (14) PCT Sample Preparation Systems during Q32008. The Company is pleased to announce that it has installed 17 PCT Systems, as compared to 7 in the second quarter of 2008. Furthermore, the Company expects to meet or exceed its previously announced full year guidance of 40 installations.
Richard T. Schumacher, President and CEO of Pressure BioSciences, Inc., commented: "The continued publications and presentations from early adopters of PCT is helping us tremendously in our commercialization efforts. We attribute a significant portion of our recent commercial success to testimonials like the ones highlighted above, that herald the merits of pressure cycling technology in various applications of life sciences, as well as the advantages of PCT over other sample preparation methods available today. We would like to congratulate our customers and collaborators for their important research studies and for their continued support of PCT."
About Pressure BioSciences, Inc.
Pressure BioSciences, Inc. (PBI) is a publicly-traded company focused on the development and commercialization of a novel, enabling technology called pressure cycling technology (PCT). PCT uses cycles of hydrostatic pressure between ambient and ultra-high levels (up to 35,000 psi and greater) to control bio-molecular interactions. PBI currently holds 13 US and 6 foreign patents covering multiple applications of PCT in the life sciences field, including in such areas as genomic and proteomic sample preparation, pathogen inactivation, the control of chemical reactions, immunodiagnostics, and protein purification.
Forward Looking Statements
Statements contained in this press release regarding the Company's
intentions, hopes, beliefs, expectations, or predictions of the future are
"forward-looking" statements within the meaning of the Private Securities
Litigation Reform Act of 1995. Such forward looking statements include
statements regarding data presented at the FACSS Meeting by scientists at
Amgen; the expected presentation by Dr. Paul Pevsner at the upcoming
Discovery2Diagnostics Conference; and expected installations of Barocycler
instruments during Q32008 and expected installations during FY2008. These
statements are based upon the Company's current expectations, forecasts,
and assumptions that are subject to risks, uncertainties, and other factors
that could cause actual outcomes and results to differ materially from
those indicated by these forward-looking statements. These risks,
uncertainties, and other factors include, but are not limited to: the
possibility that other scientists will be unable to reproduce the findings
reported by scientists at Amgen that indicate that PCT provides a most
effective method for digesting monoclonal antibodies; due to scientific and
medical challenges, the possibility that the data generated by Dr. Pevsner
and his colleagues to be presented at the October 2008
Discovery2Diagnostics Conference, may not be reproduced by other
researchers in the future; that due to competitive products, services, and
technological advances, PCT may not be the preferred method of sample
preparation by other scientists and laboratories; the possibility that due
to unforeseen issues, the Company may not install seventeen (17) PCT
Systems in Q32008 and it may not meet or exceed (40) installations in
FY2008; and the other risks and uncertainties discussed under the heading
"Risk Factors" in the Company's Annual Report on Form 10-K for the year
ended December 31, 2007, and other reports filed by the Company from time
to time with the SEC. The Company undertakes no obligation to update any of
the information included in this release, except as otherwise required by
Visit us at our website http://www.pressurebiosciences.com .
Richard T. Schumacher, President & CEO
Pressure BioSciences, Inc.
Edward H. Myles, Sr. Vice President of Finance & CFO
(508) 230-1828 (T)
|SOURCE Pressure BioSciences, Inc.|
Copyright©2008 PR Newswire.
All rights reserved